Personalis (NASDAQ: PSNL) — Perfil da empresa, notícias e dados financeiros
Personalis offers genomic sequencing solutions to support precision medicine in cancer research and treatment.
Personalis
Personalis (NASDAQ:PSNL) is a biotechnology firm focused on advancing precision medicine. The company offers comprehensive genomic sequencing and analytics solutions to support cancer research and treatment. Personalis operates with the objective of enabling researchers and clinicians to unlock deep insights into the molecular and immunological mechanisms of cancer, aiding in the development of more personalized therapeutic strategies. With an emphasis on high-quality data and innovative approaches to genetic analysis, Personalis collaborates with biopharmaceutical companies and academic institutions around the world to accelerate the pace of precision oncology. The cutting-edge technologies and services provided by Personalis strive to enhance patient outcomes, making significant contributions to the ongoing battle against cancer.
Resumo
Operações
Produtos e/ou serviços de Personalis
- NeXT Platform, a comprehensive cancer genomics platform for biomarker discovery and cancer research.
- ImmunoID NeXT, designed to provide a detailed view of the tumor and tumor microenvironment for immuno-oncology applications.
- NeXT Liquid Biopsy, offering minimally invasive cancer monitoring and detection using circulating tumor DNA.
- Personalis Diagnostics Services, providing advanced sequencing and data analysis for clinical trials and research.
- ACE Technology, enhancing sequencing accuracy and sensitivity for difficult-to-sequence regions of the genome.
- NeXT Dx Test, a clinical diagnostic test providing molecular insights for personalized cancer therapy decisions.
equipe executiva do Personalis
- Christopher M. HallCEO & Director
- Richard ChenPresident & Chief Medical Officer
- Aaron L. TachibanaCFO & COO
- Russ B. AltmanCo-Founder and Member of Clinical & Scientific Advisory Board
- Euan Angus AshleyCo-Founder and Member of Clinical & Scientific Advisory Board
- Michael P. SnyderCo-Founder and Member of Clinical & Scientific Advisory Board
- Ashish KheterpalSenior VP & Chief Information Officer
- Stephen M. MooreSenior VP, Chief Legal Officer & Corporate Secretary
- Christian HaudenschildSenior Vice President of Genomic Science
- Stephane MouradianSenior Vice President of Business Development
Principais indicadores financeiros
Resultados divulgados pela Personalis, em USD.
- Cap. de mercado
- 1,7 bi
- Receita (TTM)
- 69,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- -153.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 69,6 mi | -88,1 mi | -81,3 mi | |
| 84,6 mi | -68,3 mi | -81,3 mi | |
| 73,5 mi | -96,3 mi | -108,3 mi | |
| 65 mi | -115,5 mi | -113,3 mi |